Manager TitleAgeSince
Chief Operating Officer - 14/11/2022
Director TitleAgeSince
Director/Board Member 61 16/08/2005
Chairman 67 19/09/2014
Director/Board Member 56 05/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-23.37%-37.69% - - 12.81L
-1.79%-3.82%+38.74%+91.90% 6.9TCr
-2.06%-1.52%+46.40%+86.87% 6.63TCr
-0.31%+6.54%-11.39%+378.92% 2.77TCr
+0.86%+1.65%+0.25%-14.95% 2.58TCr
-3.00%-2.61%+34.45%+11.39% 2.65TCr
-1.46%-0.09%+24.64%-18.36% 2.04TCr
-2.96%-16.03%+213.13%+375.00% 1.76TCr
-1.49%-6.69%-4.69%+539.74% 1.51TCr
-0.20%+8.37%+57.87%+164.98% 1.47TCr
Average -3.54%-0.66%+44.37%+179.50% 3.15TCr
Weighted average by Cap. -1.50%-0.45%+40.23%+138.88%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14